



**BlueCross
BlueShield**

Federal Employee Program

**FARXIGA / JARDIANCE
PRIOR APPROVAL REQUEST**

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the provider portion and submit this completed form.

Send completed form to:
Service Benefit Plan
Prior Approval
P.O. Box 52080 MC 139
Phoenix, AZ 85072-2080
Attn: Clinical Services
Fax: 1-877-378-4727

Patient Information (required)				Provider Information (required)		
Date:				Provider Name:		
Patient Name:				Specialty:		NPI:
Date of Birth:	Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female			Office Phone:		Office Fax:
Street Address:				Office Street Address:		
City:	State:	Zip:		City:	State:	Zip:
Patient ID:	R <input type="text"/>			Physician Signature:		
PHYSICIAN COMPLETES						

NOTE: Form must be completed in its **entirety** for processing

Please select medication:	<input type="checkbox"/> Farxiga (dapagliflozin)	<input type="checkbox"/> Jardiance (empagliflozin)
----------------------------------	--	--

****Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit**

Is this request for brand or generic? ☐ Brand ☐ Generic

1. What is the patient's diagnosis?

☐ Chronic kidney disease (CKD)

a. Has the patient been on this medication continuously for the last **6 months** excluding samples? *Please select answer below:*

☐ **NO** – this is **INITIATION** of therapy, please answer the following questions:

i. Does the patient have a diagnosis of polycystic kidney disease (PKD)? ☐ Yes ☐ No

ii. Is the patient currently using or does the patient have a recent history of immunosuppressive therapy for the treatment of kidney disease (e.g., tacrolimus, sirolimus, cyclosporine, mycophenolate, etc)? ☐ Yes ☐ No

☐ **YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question:

i. Has the patient had a reduced decline in renal function? ☐ Yes ☐ No

☐ Heart failure (HF)

a. Has the patient been on this medication continuously for the last **6 months** excluding samples? ☐ Yes* ☐ No

**If YES*, has the patient's symptoms improved or stabilized with therapy? ☐ Yes ☐ No

☐ Type 2 diabetes mellitus (DM)

a. Has the patient been on this medication continuously for the last **6 months** excluding samples? ☐ Yes ☐ No*

**If NO*, please answer the following questions:

i. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to metformin? ☐ Yes ☐ No*

**If NO*, has the patient had an intolerance or contraindication or have they had an inadequate treatment response to one of the following metformin combination medications: Glucovance, Janumet/Janumet XR, Jentadueto/Jentadueto XR, Kazano, Kombiglyze XR, or Trijardy XR? ☐ Yes ☐ No

ii. **Standard Option:** Is this medication being requested as a change from one of the following to allow the member access to their copay benefit: Invokana, Invokamet, Invokamet XR, Steglatro, Steglujan, or Segluromet? ☐ Yes* ☐ No

**If YES*, select drug: ☐ Invokamet/Invokamet XR ☐ Invokana ☐ Segluromet ☐ Steglatro ☐ Steglujan

☐ Other (please specify): _____

2. Will this medication be used in combination with other SGLT2 inhibitors? ☐ Yes* ☐ No

**If YES*, please specify the medication: _____

**SGLT2 inhibitors: Brenzavvy (bexagliflozin), Farxiga (dapagliflozin), Glyxambi (empagliflozin/linagliptin), Inpefa (sotagliflozin), Invokamet/Invokamet XR (canagliflozin/ metformin), Invokana (canagliflozin), Jardiance (empagliflozin), Qtern (dapagliflozin/ saxagliflozin), Qternmet XR (dapagliflozin/saxagliflozin/metformin), Segluromet (ertugliflozin/metformin), Steglatro (ertugliflozin), Steglujan (ertugliflozin/ sitagliptin), Synjardy/Synjardy XR (empagliflozin/metformin), Trijardy XR (empagliflozin /linagliptin/ metformin), Xigduo XR (dapagliflozin/metformin)*



Federal Employee Program.

**FARXIGA / JARDIANCE
PRIOR APPROVAL REQUEST**

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the provider portion and submit this completed form.

Send completed form to:
Service Benefit Plan
Prior Approval
P.O. Box 52080 MC 139
Phoenix, AZ 85072-2080
Attn: Clinical Services
Fax: **1-877-378-4727**

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST	Now you can get responses to drug Prior Authorization requests securely online. Online submissions may receive instant responses and do not require faxing or phone calls. Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to Caremark.com/ePA .
Phone (4-5 minutes for response)	The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service. The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 days for response)	Fax the attached form to (877)-378-4727 . Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed. <u>Please only fax the completed form once as duplicate submissions may delay processing times.</u>

faster... easier... better...	Introducing ePA! Online Prior Authorizations in minutes through Caremark.com/ePA . Sign up today!
	CVS/caremark 